Lomefloxacin Hydrochloride for Injection

1. Pharmacology: This product is a quinolone antibacterial drug. It has high antibacterial activity against Enterobacteriaceae such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter, etc.; Haemophilus influenzae and Neisseria gonorrhoeae are also highly sensitive to this product; it also has certain antibacterial effects on Pseudomonas such as Acinetobacter, Pseudomonas aeruginosa, Staphylococcus, Pneumococcus, hemolytic Streptococcus, etc. This product acts on the A subunit of DNA helicase in bacterial cells, inhibiting DNA synthesis and replication to achieve bactericidal effect. 2. Toxicology: This product has a weak positive reaction only in the in vitro mutagenicity test conducted by the CHO/HGPRT method at a concentration of ge;226mu;g/ml.

The main ingredient of this product is Lomeza hydrochloride.

This product is white powder or loose lumps.

This product is suitable for the following infections caused by sensitive bacteria: 1. Respiratory tract infections: acute exacerbation of chronic bronchitis, bronchiectasis with infection, acute bronchitis and pneumonia, etc. 2. Urinary and reproductive system infections: acute cystitis, acute pyelonephritis, complicated urinary tract infection, acute exacerbation of chronic urinary tract infection, acute and chronic prostatitis, and urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains), etc. 3. Gastrointestinal bacterial infections: caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Infections of the abdominal cavity, bile duct, typhoid, etc. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis. 8. Other infections, such as sinusitis, otitis media, blepharitis, etc.

Intravenous drip: 0.2 g once, twice a day. For urinary tract infection: 0.1 g once, twice a day, for 7 to 14 days. Dissolve this product in 250 ml of 5% to 10% glucose injection or sodium chloride injection and drip slowly before use.

1. Gastrointestinal reactions: relatively common, may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions: may cause dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, itchy skin, occasionally exudative erythema multiforme and angioneurotic edema. Photosensitivity reactions are more common than other commonly used quinolones. 4. A small number of patients may experience increased serum aminotransferase and BUN values and decreased peripheral blood white blood cells, which are mostly mild and transient. 5. Occasionally may occur: (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. (2) interstitial nephritis manifestations such as hematuria, fever, rash. (3) crystalluria, more common when used in high doses. (4) joint pain. (5) phlebitis.

1. It is contraindicated for patients who are allergic to this product or other quinolone drugs. 2. It is contraindicated for pregnant women, infants and patients under 18 years old.

1. This product has little effect on the liver metabolism and body clearance of theophylline drugs and caffeine. 2. Combination with fenbufen can cause central nervous system excitation and epileptic seizures. 3. Probenecid can delay the excretion of this product, increase the average area under the curve (AUC) by 63%, prolong the average time to peak (tmax) by 50%, and increase the average peak concentration (Cmax) by 4%; therefore, when used together, it may cause toxicity due to the increase in blood concentration of this product. 4. It can enhance the effect of oral anticoagulants such as warfarin, and the prothrombin time and other items should be monitored. 5. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 6. Combination with cyclosporine can increase the blood concentration of cyclosporine, and the blood concentration of cyclosporine must be monitored and the dosage adjusted.

Keep away from light and store in a sealed container.

0.2g (as lomefloxacin)

Fuan Pharmaceutical Group Hubei Renmin Pharmaceutical Co., Ltd.

• Founded in:

  2001-11-13

• Address:

  No. 1 Qijiashante, Baiquan, Dongxihu District, Wuhan

• Tax NO.:

  91420112732707909X

• Registered Funds:

  111.99 million yuan

• Website:

  Log in to view

• Email:

  Log in to view